Tartrate-resistant acid phosphatase 5b is a marker of osteoclast number and volume in RAW 264.7 cells treated with receptor-activated nuclear κB ligand

YUANDONG LV, GUIHUA WANG, WEIHONG XU, PINGHUA TAO, XIAOLING LV and YAZHEN WANG

Zhejiang Provincial Key Laboratory of Geriatrics, Zhejiang Hospital, Hangzhou, Zhejiang 310013, P.R. China

Received March 14, 2014; Accepted October 24, 2014

DOI: 10.3892/etm.2014.2071

Abstract. Tartrate-resistant acid phosphatase 5b (TRACP 5b) has been used as a biomarker of bone resorption and cancer metastasis. TRACP 5b has also been suggested to be a reliable marker of osteoclast number. In this study, the correlation of TRACP 5b level and osteoclast-like cell number was investigated in RAW 264.7 cells treated with receptor-activated nuclear factor κB ligand (RANKL). RAW 264.7 cells were cultured with α-MEM containing RANKL (40 ng/ml) for 3, 5 and 7 days. Osteoclast formation and TRACP 5b levels were determined by TRACP staining, scanning electron microscopy and enzyme-linked immunosorbent assay. The RAW 264.7 cells that were not exposed to RANKL did not secrete TRACP 5b. RANKL induced the RAW 264.7 cells to differentiate into osteoclasts and to secrete TRACP 5b. The TRACP 5b level in the RAW 264.7 cells treated with RANKL was significantly correlated with the number and volume of osteoclasts (r=0.95 and r=0.92, respectively; P<0.0001). TRACP 5b is a good marker of RANKL-induced osteoclast formation in RAW 264.7 cells. TRACP 5b analysis may be used as an alternative to osteoclast counting in vitro.

Introduction

Osteoclasts are important cells involved in bone resorption. They are multinucleated cells derived from hematopoietic cells (1-3). In the presence of receptor-activated nuclear factor κB ligand (RANKL) and macrophage colony-stimulating factor (M-CSF), hematopoietic precursor cells differentiate into mature osteoclasts, which are fused polykaryons arising from multiple monocytic cells (3,4).

Materials and methods

RAW 264.7 cell culture. The RAW 264.7 mouse monocyte/macrophage cell line (American Type Culture Collection number, TIB-71) was obtained as a gift from Dr Hui Sheng (Department of Orthopedics and Traumatology, The Chinese University of Hong Kong, Hong Kong, China). The cells have the capacity to differentiate into osteoclast-like cells in the presence of RANKL (12,13). RAW 264.7 cells have been widely used and accepted as a cell model of osteoclast formation and function in biology and pharmacology (14,15). However, to the best of our knowledge, no studies have investigated whether TRACP 5b can be used as an indicator of osteoclast number in RAW 264.7 cell-derived osteoclasts. In the present study, using the RAW 264.7 cell line, the association of TRACP 5b and the number of osteoclasts was investigated.

Numerous in vitro models of osteoclast differentiation have been developed. It has been suggested that bone marrow cells (5), spleen cells (6) and blood monocytes (7) are able to differentiate into osteoclasts in the presence of certain specific factors. Tartrate-resistant acid phosphatase 5b (TRACP 5b) is one of several bone metabolic biomarkers that are specifically secreted by osteoclasts (8,9) and has been used as biomarker of bone resorption and cancer metastasis. Alatalo et al (10) and Rissanen et al (11) have shown that TRACP 5b is a good indicator of osteoclast number in mouse bone marrow-derived osteoclasts and human blood monocyte-derived osteoclasts.

The mouse macrophage cell line RAW 264.7 is a transflectable monocyte/macrophage cell line that retains the capacity to differentiate into osteoclast-like cells in the presence of RANKL (12,13). RAW 264.7 cells have been widely used and accepted as a cell model of osteoclast formation and function in biology and pharmacology (14,15). However, to the best of our knowledge, no studies have investigated whether TRACP 5b can be used as an indicator of osteoclast number in RAW 264.7 cell-derived osteoclasts. In the present study, using the RAW 264.7 cell line, the association of TRACP 5b and the number of osteoclasts was investigated.

TRACP staining. RAW 264.7 cells were cultured with α-MEM containing RANKL (40 ng/ml) for 3, 5 and 7 days with a change of medium every 2 days. The cells were fixed and stained for TRACP using an Acid Phosphatase, Leukocyte (TRAP) staining kit (catalog number, 387A; Sigma-Aldrich) according to the manufacturer's instructions. Cells that were
et al: TARTRATE-RESISTANT ACID PHOSPHATASE 5B AS MARKER OF RAW 264.7 DIFFERENTIATION

stained red were considered to be differentiated osteoclast-like cells and multinucleated cells were those comprising ≥3 nuclei. The number of TRACP+ cells was counted using Simple PCI imaging software (Compix Inc., Cranberry, PA, USA) by two individuals who were blinded to the previous treatment of the cells.

Scanning electron microscope (SEM) examination. RAW 264.7 cells were cultured on glass slides with α-MEM containing RANKL (40 ng/ml) for 3, 5 and 7 days with a change of medium every two days. The RAW 264.7 cells were fixed using 4% paraformaldehyde and SEM analysis was conducted using a Hitachi S520 SEM (Hitachi Ltd., Tokyo, Japan). The slices were mounted on the SEM stub with carbon tape and carbon coated prior to analysis.

TRACP 5b assay. RAW 264.7 cells were cultured with α-MEM containing RANKL (40 ng/ml) for 3, 5 and 7 days with a change of medium every two days and the supernatants on days 3, 5 and 7 were collected and stored at -80°C. A MouseTRAP™ enzyme immunoassay (EIA) kit (Immunodiagnostic Systems Ltd., Boldon, UK) was used in the determination of the level of TRACP 5b in the supernatants according to the instructions provided by the manufacturer. The intra-assay variation of the method for TRACP 5b was <6.5% and the inter-assay variation was <8%. The standard sample supplied by the kit was 2.0 (1.6-2.5) U/l, and the obtained result in our laboratory was 1.94 U/l.

Statistical analysis. SPSS software, version 11.5 (SPSS Inc., Chicago, IL, USA) was used for statistical analysis. Data are represented as the mean ± standard deviation. The correlation of the TRACP 5b level and the number of osteoclasts was analyzed using Pearson correlation analysis. P<0.05 was considered to indicate a statistically significant difference.

Results

TRACP-positive cell formation. The results of the TRACP staining assay indicated that RANKL induced the formation of osteoclasts from RAW 264.7 cells. No clearly TRAP+ cells were observed in the untreated RAW 264.7 cells (Fig. 1A). A number of multinucleated (≥3 nuclei) giant cells were formed in the RAW 264.7 cells that were treated with 40 ng/ml RANKL for 5 and 7 days (Fig. 1B). SEM showed the osteoclast-like cells were larger, darker, branched cells with a number of microvilli (Fig. 1C). Furthermore, the number of TRAP+ cells was determined. The results indicated that RANKL induced a marked increase in the number of TRAP+ cells (Fig. 2).

Figure 1. Tartrate-resistant acid phosphatase (TRACP) staining and scanning electron microscope (SEM) images of RAW 264.7 cells in the presence and absence of receptor-activated nuclear κB ligand (RANKL). TRACP staining of cells cultured for 3, 5 and 7 days (A) without and (B) with RANKL. (C) SEM imaging of cells cultured for 3, 5 and 7 days in the presence of RANKL. Top panels, 3 days; middle panels, 5 days; bottom panels, 7 days. For 1A and 1B, magnification, ×40. For 1C, magnification, ×400.
TRACP 5b level. The TRACP 5b level in the RAW 264.7 cells was examined using an EIA kit. TRACP 5b was detected in the RAW 264.7 cells following treatment with RANKL for 3, 5 and 7 days, and the level of TRACP 5b increased as the culture time increased (Fig. 3).

Correlation of TRACP 5b with osteoclast number and volume. The results of the correlation analysis, presented in Figs. 4 and 5, indicate that number and volume of osteoclast-like cells was significantly correlated with the level of TRACP 5b released into the medium (r=0.95 and 0.92, respectively; P<0.001).

Discussion

In the present study, it was demonstrated that RANKL induced RAW 264.7 cell fusion to form mature osteoclasts. The level of TRACP 5b secreted into the culture medium by the RAW 264.7 cell-derived osteoclast-like cells was significantly correlated with the number of osteoclastic-like cells formed. These results suggest that TRACP 5b analysis may be used as an alternative to the microscopic counting of osteoclasts differentiated from RAW 264.7 cells with the presence of RANKL.

TRACP 5b has been used in the diagnosis of bone diseases (16,17), such as osteoporosis and bone metastasis, and for monitoring antiresorptive treatment (18). It has been suggested that TRACP 5b levels may reflect the status of bone resorption (9). TRACP 5b levels have been shown to correlate with the number of osteoclasts in patients with osteoporosis (19) and renal bone disease (20). However, to the best of our knowledge, no studies have investigated the correlation of TRACP 5b levels with osteoclast number in vitro.

In the present study, it was observed that RAW 264.7 cells cultured with RANKL secreted TRACP 5b constitutively into the medium. The TRACP 5b level was correlated with the number of osteoclast-like cells. The data were consistent with the results observed by Alatalo et al (10). However, there was a certain difference in the findings. The plot of osteoclast number and TRACP 5b data in the present study formed a curve, not a straight line as was observed for the data provided by Alatalo et al (10) and Rassanen et al (11). The data appeared to fit a binomial curve. This may be due to the different cell type used in the present study. In addition, it is speculated that the TRACP 5b level may not be only associated with the osteoclast number, but also with osteoclast size. Big osteoclasts may
secrete greater amounts of TRACP 5b into the culture medium compared with that secreted by smaller osteoclasts.

An increasing number of studies have adopted RAW 264.7 cell as a source of osteoclasts to study the effects of potential therapeutic agents on bone diseases (21,22) and to conduct osteoclast-related research (23-25). Thus, it would be of benefit to develop new methods for quantifying osteoclasts as an alternative to osteoclast counting using light microscopy. The data from the present study indicate that TRACP 5b immunoassay may be a fast and reliable method to replace time-consuming osteoclast counting.

References

1. Viinäinen HK, Zhao H, Mulari M and Halleen JM: The cell biology of osteoclast function. J Cell Sci 113: 377-381, 2000.
2. Blair HC and Athanassou NA: Recent advances in osteoclast biology and pathological bone resorption. Histol Histopathol 19: 189-199, 2004.
3. Boyle WJ, Simonet WS and Lacey DL: Osteoclast differentiation and activation. Nature 423: 337-342, 2003.
4. Cuetara BV, Crotti TN, O'Donoghue AJ and McHugh KP: Cloning and characterization of osteoclast precursors from the RAW264.7 cell line. In Vitro Cell Dev Biol Anim 42: 182-188, 2006.
5. MacDonald BR, Takahashi N, et al: Formation of multinucleated cells that respond to osteotropic hormones in long term human bone marrow cultures. Endocrinology 120: 2326-2333, 1987.
6. Udagawa N, Takahashi N, Akatsu T, et al: Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. Proc Natl Acad Sci USA 87: 7260-7264, 1990.
7. Higuchi S, Tabata N, Tajima M, et al: Induction of human osteoclast-like cells by treatment of blood monocytes with anti-fusion regulatory protein-1/CD98 monoclonal antibodies. J Bone Miner Res 13: 44-49, 1998.
8. Halleen JM, Alatalo SL, Suominen H, et al: Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. J Bone Miner Res 15: 1337-1345, 2000.
9. Halleen JM, Tiitinen SL, Ylipahkala H, Fagerlund KM and Viinäinen HK: Tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of bone resorption. Clin Lab 52: 498-509, 2006.
10. Alatalo SL, Halleen JM, et al: Rapid screening method for osteoclast differentiation in vitro that measures tartrate-resistant acid phosphatase 5b activity secreted into the culture medium. Clin Chem 46: 1751-1754, 2000.
11. Rissanen JB, Suominen MI, Peng ZQ and Halleen JM: Secreted tartrate-resistant acid phosphatase 5b is a marker of osteoclast number in human osteoclast cultures and the rat ovariectomy model. Calcif Tissue Int 82: 108-115, 2008.
12. Hsu H, Lacey DL, Dunstan CR, et al: Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 96: 3540-3545, 1999.
13. Thompson CD, Frazier-Jessen MR, Rawat R, Nordan RP and Brown RT: Evaluation of methods for transient transfection of a murine macrophage cell line, RAW 264.7. Biotechniques 27: 824-832, 1999.
14. Yu X, Huang Y, Collin-Osdoby P and Osdoby P: CCRI chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts. J Bone Miner Res 19: 2065-2077, 2004.
15. Battaglino R, Fu J, Späte U, et al: Serotonin regulates osteoclast differentiation through its transporter. J Bone Miner Res 19: 1420-1431, 2004.
16. Mose S, Menzel C, Kurth AA, et al: Evaluation of tartrate-resistant acid phosphatase (TRACP) 5b as bone resorption marker in irradiated bone metastases. Anticancer Res 25: 4639-4645, 2005.
17. Qin YJ, Zhang ZL, Zhang H, et al: Age-related changes of serum tartrate-resistant acid phosphatase 5b and the relationship with bone mineral density in Chinese women. Acta Pharmacol Sin 29: 1493-1498, 2008.
18. Nenonen A, Cheng S, Ivaska KK, et al: Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover. J Bone Miner Res 20: 1804-1812, 2005.
19. Alatalo SL, Ivaska KK, Waguespack SG, et al: Osteoclast-derived serum tartrate-resistant acid phosphatase 5b in Albers-Schonber disease (type II autosomal dominant osteopetrosis). Clin Chem 50: 883-890, 2004.
20. Alatalo SL, Ivaska KK, Peng Z, et al: Serum tartrate-resistant acid phosphatase 5b and osteocalcin in naturally occurring osteopetrotic rats. J Bone Miner Res 18 (Suppl): S95, 2003.
21. Xiao KH, Liao EY, Zhou HD, et al: Ascorbic acid inhibits osteoclastogenesis of RAW264.7 cells induced by receptor activated nuclear factor kappaB ligand (RANKL) in vitro. J Endocrinol Invest 28: 253-260, 2005.
22. Abe K, Yoshimura Y, Deyama Y, et al: Effects of bisphosphonates on osteoclastogenesis in RAW264.7 cells. Int J Mol Med 29: 1007-1015, 2012.
23. Teramachi J, Morimoto H, Baba R, et al: Double stranded RNA-dependent protein kinase is involved in osteoclast differentiation of RAW264.7 cells in vitro. Exp Cell Res 316: 3254-3262, 2010.
24. GuezGuez A, Prod'homme V, Mouska X, et al: 3BP2 Adapter protein is required for receptor activator of NF kappaB ligand (RANKL)-induced osteoclast differentiation of RAW264.7 cells. J Biol Chem 285: 20952-20963, 2010.
25. Nishida T, Emura K, Kubota S, Lyons KM and Takigawa M: CCN family 2/connective tissue growth factor (CCN2/CTGF) promotes osteoclastogenesis via induction of and interaction with dendritic cell-specific transmembrane protein (DC-STAMP). J Bone Miner Res 26: 351-363, 2011.